The estimated Net Worth of Peter G Schultz is at least $5.41 Миллион dollars as of 5 June 2015. Peter Schultz owns over 46,729 units of Ardelyx Inc stock worth over $5,408,277 and over the last 10 years Peter sold ARDX stock worth over $0.
Peter has made over 1 trades of the Ardelyx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Peter bought 46,729 units of ARDX stock worth $500,000 on 5 June 2015.
The largest trade Peter's ever made was buying 46,729 units of Ardelyx Inc stock on 5 June 2015 worth over $500,000. On average, Peter trades about 15,576 units every 0 days since 2014. As of 5 June 2015 Peter still owns at least 907,429 units of Ardelyx Inc stock.
You can see the complete history of Peter Schultz stock trades at the bottom of the page.
Peter's mailing address filed with the SEC is C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT, CA, 94555.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell и Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: